Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647403 | 0.81 | ALOX15 (0.33) | MAPTAPLNR | |
| SCHEMBL23863870 | 0.76 | CHRNB2 (0.36) | APLNR | |
| SCHEMBL16885302 | 0.75 | EPHX1 (0.33) | SMN1; SMN2EPHX1 | |
| SCHEMBL14446943 | 0.70 | APLNR (0.44) | SMN1; SMN2MAPTEPHX1APLNRKDM4E | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 | 0.68 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTEPHX1KDM4EKMT2A | |
| SCHEMBL28418543 | 0.68 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTEPHX1KDM4EKMT2A | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.68 | — | — | |
| SCHEMBL9797557 | 0.68 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTEPHX1KDM4EKMT2A | |
| SCHEMBL383436 | 0.68 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTEPHX1KDM4EKMT2A | |
| SCHEMBL13332956 | 0.68 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTEPHX1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | SMN1; SMN2 4721/4885MAPT 4283/4885EPHX1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.